Showing results (51-60 of 154) with videos related to
Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjectsJacob Lalezari, Joseph Gathe, Cynthia Brinson, et al.HIV Clinical Trials|May 14, 2008
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabineEdwin DeJesus, Peter Ruane, Cheryl McDonald, et al.AIDS (London, England)|July 1, 2011
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adultsSherene Min, Louis Sloan, Edwin DeJesus, et al.AIDS (London, England)|May 26, 2018
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamidePaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.BMC Infectious Diseases|June 8, 2013
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week resultsPrincy Kumar, Edwin DeJesus, Gregory Huhn, et al.AIDS Research and Human Retroviruses|July 1, 2009
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)Lisa Ross, Richard Elion, Randall Lanier, et al.AIDS Research and Therapy|April 1, 2008
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERTKimberly Y Smith, Winkler G Weinberg, Edwin DeJesus, et al.AIDS Research and Human Retroviruses|April 13, 2010
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patientsLisa L Ross, Winkler G Weinberg, Edwin DeJesus, et al.AIDS (London, England)|July 9, 2010
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsKathleen E Squires, Benjamin Young, Edwin Dejesus, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2006
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsEdwin DeJesus, Daniel Berger, Martin Markowitz, et al.Pageof 16